What is CoRegen?
CoRegen Diagnostics operates at the intersection of biotechnology and clinical oncology, specializing in the development of sophisticated molecular diagnostic tests. By leveraging deep genetic analysis of tumor samples, the company provides actionable insights that enable clinicians to tailor therapeutic interventions to the unique genetic profile of each patient. This precision-oriented approach is designed to optimize treatment efficacy and improve patient outcomes in complex cancer cases. As the demand for personalized medicine continues to accelerate, CoRegen is positioned as a critical player in the diagnostic ecosystem, bridging the gap between genomic data and bedside clinical decision-making.
How much funding has CoRegen raised?
CoRegen has raised a total of $106.5M across 2 funding rounds:
Other Financing Round
$93M
Stock/Share Issuance
$13.5M
Other Financing Round (2025): $93M, investors not publicly disclosed
Stock/Share Issuance (2026): $13.5M, investors not publicly disclosed
Key Investors in CoRegen
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for CoRegen?
With this latest infusion of capital, CoRegen is well-positioned to scale its diagnostic platform and expand its footprint in the global oncology market. The company is expected to prioritize the acceleration of its R&D pipeline, focusing on the validation of new biomarkers and the expansion of its test menu to cover a broader spectrum of malignancies. Furthermore, the strategic allocation of these funds will likely support the enhancement of its commercial infrastructure, facilitating broader adoption of its diagnostic solutions among major healthcare providers and research institutions. As the firm transitions into this next phase of growth, the focus will remain on clinical utility and the integration of its diagnostic tools into standard-of-care protocols for cancer treatment.
See full CoRegen company page
